{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:30:46Z","timestamp":1792794646838,"version":"4.5.0"},"reference-count":56,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malnutrition is associated with a greater risk of morbidity and mortality and lower tolerance to chemotherapy. Our purpose was to study the association between nutritional status and the efficiency and tolerance of immunotherapy in non-small cell lung cancer (NSCLC). Nutritional and oncological data were reported at 2 months (M2) and 4 months (M4) after the initiation of immunotherapy (M0). The influence of nutritional status at M0 was estimated with the efficacy and toxicity of immunotherapy at M2 to M4. In total, 127 patients were included in the study, and nutritional status was estimated at M0 for 120 patients: 67% were not malnourished, 20% presented with moderate malnutrition, and 13% presented with severe malnutrition. There was no significant link between the nutritional status at M0 and the toxicity of immunotherapy at M2 and M4. However, severe malnutrition was significantly associated with treatment efficacy at M2 (p = 0.04) and with a lower survival rate with an HR (Hazard Ratio) = 2.32\u201395% C.I: 1.13\u20134.75 (p = 0.02). Furthermore, a monthly decrease of 1% of the weight had an HR = 1.17\u201395% C.I: 1.13\u20131.21 (p = 0.0001). Severe malnutrition and weight loss are independent factors associated with lower survival. Studies integrating the systemic detection of sarcopenia with a closer nutritional follow-up could highlight an improvement in survival.<\/jats:p>","DOI":"10.3390\/cancers14143439","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T21:00:28Z","timestamp":1658091628000},"page":"3439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Manon","family":"Gouez","sequence":"first","affiliation":[{"name":"Department of Prevention Cancer Environment, L\u00e9on B\u00e9rard Cancer Centre, 69008 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-5390","authenticated-orcid":false,"given":"Lidia","family":"Delrieu","sequence":"additional","affiliation":[{"name":"Residual Tumour & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0451-7720","authenticated-orcid":false,"given":"Carole","family":"Bouleuc","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut Curie, Institut du Thorax Curie Montsouris, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-2440","authenticated-orcid":false,"given":"Bruno","family":"Raynard","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Unit\u00e9 Transversale de Di\u00e9t\u00e9tique et de Nutrition Centre Gustave-Roussy, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-6230","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Marchal","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Institut Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non\u2013Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JTO.0b013e31819d18e5","article-title":"A Structured Exercise Program for Patients with Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Temel","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/109662101750290191","article-title":"Symptom Frequency and Severity in Patients with Metastatic or Locally Recurrent Lung Cancer: A Prospective Study Using the Lung Cancer Symptom Scale in a Community Hospital","volume":"4","author":"Lutz","year":"2001","journal-title":"J. Palliat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdy474","article-title":"Correction to: \u201cMetastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u201d","volume":"30","author":"Planchard","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","article-title":"Prevalence and Predictive Value of Pre-Therapeutic Sarcopenia in Cancer Patients: A Systematic Review","volume":"37","author":"Pamoukdjian","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_9","first-page":"1","article-title":"Nutrition Support and Dietary Interventions for Patients with Lung Cancer: Current Insights","volume":"7","author":"Kiss","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s00520-021-06603-0","article-title":"The Prevalence of CT-Defined Low Skeletal Muscle Mass in Patients with Metastatic Cancer: A Cross-Sectional Multicenter French Study (the SCAN Study)","volume":"30","author":"Raynard","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","article-title":"Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss","volume":"33","author":"Martin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.smhs.2020.10.003","article-title":"Development and Progression of Cancer Cachexia: Perspectives from Bench to Bedside","volume":"2","author":"Lim","year":"2020","journal-title":"Sports Med. Health Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.2147\/CMAR.S261585","article-title":"Cancer Cachexia: Definition, Staging, and Emerging Treatments","volume":"12","author":"Ni","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.annonc.2021.05.793","article-title":"Nutritional Support during the Hospital Stay Reduces Mortality in Patients with Different Types of Cancers: Secondary Analysis of a Prospective Randomized Trial","volume":"32","author":"Bargetzi","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bulcan.2016.10.001","article-title":"ConSoRe: Un outil permettant de rentrer dans le monde du big data en sant\u00e9","volume":"103","author":"Heudel","year":"2016","journal-title":"Bull. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of Cumulative Prognostic Scores Based on the Systemic Inflammatory Response in Patients with Inoperable Non-Small-Cell Lung Cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The Systemic Inflammation-Based Glasgow Prognostic Score: A Decade of Experience in Patients with Cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bjc.2017.274","article-title":"Predicting Response and Toxicity to Immune Checkpoint Inhibitors Using Routinely Available Blood and Clinical Markers","volume":"117","author":"Hopkins","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Iivanainen, S., and Koivunen, J.P. (2020). Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020556"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.21037\/atm.2016.06.24","article-title":"Immunotherapy in Non-Small Cell Lung Cancer: The Clinical Impact of Immune Response and Targeting","volume":"4","author":"Mountzios","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer Cachexia Syndrome and Clinical Outcome in Patients with Metastatic Non-Small Cell Lung Cancer Treated with PD-1\/PD-L1 Inhibitors: Results from a Prospective, Observational Study","volume":"10","author":"Rounis","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00520-003-0568-z","article-title":"Cancer: Disease and Nutrition Are Key Determinants of Patients\u2019 Quality of Life","volume":"12","author":"Ravasco","year":"2004","journal-title":"Support. Care Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00520-003-0486-0","article-title":"Evaluation of Nutritional Status in Advanced Metastatic Cancer","volume":"11","author":"Sarhill","year":"2003","journal-title":"Support. Care Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00520-006-0091-0","article-title":"Symptoms and Weight Loss in Patients with Gastrointestinal and Lung Cancer at Presentation","volume":"15","author":"Khalid","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-Associated Cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrc3500","article-title":"Beyond TGF\u03b2: Roles of Other TGF\u03b2 Superfamily Members in Cancer","volume":"13","author":"Wakefield","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle Wasting in Disease: Molecular Mechanisms and Promising Therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/fon.10.20","article-title":"Are Tumoral Factors Responsible for Host Tissue Wasting in Cancer Cachexia?","volume":"6","author":"Tisdale","year":"2010","journal-title":"Future Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer Cachexia: Understanding the Molecular Basis","volume":"14","author":"Busquets","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-18-1847","article-title":"Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?","volume":"24","author":"Coss","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and Classification of Cancer Cachexia: An International Consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-Tumor Immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.12.008","article-title":"Correlation between Nivolumab Exposure and Treatment Outcomes in Non\u2013Small-Cell Lung Cancer","volume":"109","author":"Basak","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00228-021-03199-6","article-title":"Impacts of Cachexia Progression in Addition to Serum IgG and Blood Lymphocytes on Serum Nivolumab in Advanced Cancer Patients","volume":"78","author":"Abe","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia-Sarcopenia as a Determinant of Disease Control Rate and Survival in Non-Small Lung Cancer Patients Receiving Immune-Checkpoint Inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.21873\/anticanres.14734","article-title":"Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer","volume":"40","author":"Fujii","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"LMT31","DOI":"10.2217\/lmt-2020-0008","article-title":"Pretreatment Nutritional Status and Response to Checkpoint Inhibitors in Lung Cancer","volume":"9","author":"Lee","year":"2020","journal-title":"Lung Cancer Manag."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Nishioka, N., Uchino, J., Hirai, S., Katayama, Y., Yoshimura, A., Okura, N., Tanimura, K., Harita, S., Imabayashi, T., and Chihara, Y. (2019). Association of Sarcopenia with and Efficacy of Anti-PD-1\/PD-L1 Therapy in Non-Small-Cell Lung Cancer. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040450"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jcsm.12698","article-title":"The Prognostic Value of Weight and Body Composition Changes in Patients with Non-small-cell Lung Cancer Treated with Nivolumab","volume":"12","author":"Degens","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjc.6605578","article-title":"Prevalence, Risk Factors and Clinical Implications of Malnutrition in French Comprehensive Cancer Centres","volume":"102","author":"Pressoir","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdy114","article-title":"Systematic Review and Meta-Analysis of the Evidence for Oral Nutritional Intervention on Nutritional and Clinical Outcomes during Chemo(Radio)Therapy: Current Evidence and Guidance for Design of Future Trials","volume":"29","author":"Laviano","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1017\/S0029665118000186","article-title":"Barriers to Cancer Nutrition Therapy: Excess Catabolism of Muscle and Adipose Tissues Induced by Tumour Products and Chemotherapy","volume":"77","author":"Schiessel","year":"2018","journal-title":"Proc. Nutr. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nupar.2012.10.006","article-title":"Nutrition chez le patient adulte atteint de cancer: Quand doit-on proposer un conseil di\u00e9t\u00e9tique personnalis\u00e9 ?","volume":"26","author":"Meuric","year":"2012","journal-title":"Nutr. Clin. M\u00e9tab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nupar.2012.10.002","article-title":"Nutrition chez le patient adulte atteint de cancer: Textes courts","volume":"26","author":"Senesse","year":"2012","journal-title":"Nutr. Clin. M\u00e9tab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1758835919880084","DOI":"10.1177\/1758835919880084","article-title":"From Guidelines to Clinical Practice: A Roadmap for Oncologists for Nutrition Therapy for Cancer Patients","volume":"11","author":"Muscaritoli","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.clnu.2020.01.009","article-title":"The Effect of Nutritional Counseling on Muscle Mass and Treatment Outcome in Patients with Metastatic Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial","volume":"39","author":"Langius","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2017.10.015","article-title":"Nutritional Counseling with or without Systematic Use of Oral Nutritional Supplements in Head and Neck Cancer Patients Undergoing Radiotherapy","volume":"126","author":"Cereda","year":"2018","journal-title":"Radiother Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2005.02.054","article-title":"Dietary Counseling Improves Patient Outcomes: A Prospective, Randomized, Controlled Trial in Colorectal Cancer Patients Undergoing Radiotherapy","volume":"23","author":"Ravasco","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00520-019-04999-4","article-title":"A Systematic Review Examining Nutrition Support Interventions in Patients with Incurable Cancer","volume":"28","author":"Blackwood","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1915138","DOI":"10.1001\/jamanetworkopen.2019.15138","article-title":"Association of Nutritional Support With Clinical Outcomes Among Medical Inpatients Who Are Malnourished or at Nutritional Risk: An Updated Systematic Review and Meta-Analysis","volume":"2","author":"Gomes","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nupar.2016.10.124","article-title":"Prise en charge nutritionnelle dans les parcours de soins des cancers","volume":"30","author":"Bachmann","year":"2016","journal-title":"Nutr. Clin. M\u00e9tab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A Multicenter Study of Body Mass Index in Cancer Patients Treated with Anti-PD-1\/PD-L1 Immune Checkpoint Inhibitors: When Overweight Becomes Favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic Effect of Weight Loss Prior Tochemotherapy in Cancer Patients","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1724600818799876","article-title":"Prognostic Value of Pretreatment Prognostic Nutritional Index in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"33","author":"Hu","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.21037\/atm-21-4528","article-title":"Long-Term and Short-Term Prognostic Value of the Prognostic Nutritional Index in Cancer: A Narrative Review","volume":"9","author":"Yan","year":"2021","journal-title":"Ann. Transl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:51:02Z","timestamp":1760140262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":56,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14143439"],"URL":"https:\/\/doi.org\/10.3390\/cancers14143439","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}